MARK KESSEL
CIK 1222013 · last filed 2019-09-09
MARK KESSEL is a corporate insider who has filed 16 SEC Form 4 insider transactions across 3 companies since 2009. The most recent filing, for ONVO, was dated Sep 9, 2019. Across all open-market trades the lifetime net is −$28.4M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
16
-$28.36M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VivoSim Labs, INC. (ONVO) Delisted | Director | 15,000 | $2.04 | $30.6K | $0 | 4 | 2019-09-09 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Director | 3,031,431 | $15.50 | $46.99M | -$28.36M | 7 | 2012-10-17 |
| Oncotelic Therapeutics, Inc. (OXGN) Delisted | Director | 27,232,118 | — | — | $0 | 5 | 2011-01-04 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-09-09 | VivoSim Labs, INC. (ONVO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-30 | VivoSim Labs, INC. (ONVO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-28 | VivoSim Labs, INC. (ONVO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-19 | VivoSim Labs, INC. (ONVO) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2012-10-17 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Sell (S) | −6,000,000 | -$28.36M | EDGAR |
| 2012-05-31 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-03-12 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-03 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-01-04 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Grant (A) | +25,000 | $5.8K | EDGAR |
| 2010-07-06 | Oncotelic Therapeutics, Inc. (OXGN) Delisted | Grant (A) | +25,000 | $9.5K | EDGAR |